Dovitinib Lactate, Gemcitabine Hydrochloride, and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced Solid Tumors or Pancreatic Cancer

• Status: Withdrawn
• Trial end date: 1969-12-31

Summary

This phase I trial studies the highest and safest doses of dovitinib lactate, paclitaxel albumin-stabilized nanoparticle formulation, and gemcitabine hydrochloride when given together. Dovitinib lactate disrupts the activity of fibroblast growth factor receptors and reduces cancer growth and spread. Gemcitabine hydrochloride and paclitaxel albumin-stabilized nanoparticle formulation are anti-cancer drugs for treating many cancer types.

• Phase: Phase 1

Details

• Lead Sponsor: Roswell Park Cancer Institute
• Collaborators: National Cancer Institute (NCI); Novartis
• Treatments: Albumin-Bound Paclitaxel; Gemcitabine; Paclitaxel